Department of Nursing, School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Clin Nurs Res. 2023 May;32(4):705-711. doi: 10.1177/10547738231159062. Epub 2023 Mar 13.
Ondansetron is a widely administered medication for nausea and vomiting of pregnancy. Further examination of its teratogenic capacity is necessary. This study examines the association between ondansetron treatment during pregnancy and birth defects and adverse obstetric outcomes. Patient data were extracted from Clalit Health Services, Israel. A propensity-score analysis was performed matching those exposed to ondansetron with those who were not. Findings identified 774 women exposed to ondansetron, matched 1:1 with unexposed control patients. No significant differences were found between the groups for: cleft palate, cardiovascular congenital abnormalities, spina bifida occulta, preterm delivery, or small for gestational age. Ondansetron may be a useful and safe alternative as treatment for women who suffer from hyperemesis gravidarum and do not respond to other antiemetic drugs. Notwithstanding, additional prospectively designed research is needed to establish the safety of ondansetron treatment during pregnancy.
昂丹司琼广泛用于治疗妊娠恶心和呕吐。有必要进一步研究其致畸能力。本研究探讨了妊娠期间昂丹司琼治疗与出生缺陷和不良产科结局之间的关系。患者数据从以色列的克利夫健康服务机构中提取。采用倾向评分分析将暴露于昂丹司琼的患者与未暴露的对照组患者进行匹配。结果发现，774 名女性暴露于昂丹司琼，与未暴露的对照组患者 1:1 匹配。两组之间在腭裂、心血管先天性异常、隐性脊柱裂、早产或小于胎龄儿方面无显著差异。昂丹司琼可能是一种有用且安全的替代治疗方法，适用于患有妊娠剧吐且对其他止吐药物无反应的女性。然而，仍需要前瞻性设计的研究来确定妊娠期间使用昂丹司琼治疗的安全性。
